Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06959225 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
A Phase 3 study of Hidradenitis Suppurativa, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 550
- Enrollment target
- 20
- Study locations
NCT06959225 is a Phase 3 study of Hidradenitis Suppurativa that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 550 participants, roughly in line with the 588-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target. The trial reports 20 study locations across 6 states.
The verdict
NCT06959225, a Phase 3 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 550 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Conditions Studied
Interventions
- DRUG Ruxolitinib Cream
- DRUG Vehicle Cream
Study Locations (20)
California
- Investigative Site US055 - Brea
- Investigative Site US004 - Laguna Niguel
- Investigative Site US007 - Los Angeles
- Investigative Site US013 - San Diego
- Investigative Site US060 - San Diego
- Investigative Site US038 - San Diego
Florida
- Investigative Site US045 - Boynton Beach
- Investigative Site US028 - Fort Myers
- Investigative Site US016 - Miami
- Investigative Site US027 - Sanford
- Investigative Site US057 - Sweetwater
- Investigative Site US029 - Tampa
Arizona
- Investigative Site US020 - Phoenix
- Investigative Site US033 - Scottsdale
- Investigative Site US054 - Tempe
Georgia
- Investigative Site US061 - Atlanta
- Investigative Site US053 - Atlanta
- Investigative Site US019 - Marietta
Arkansas
- Investigative Site US002 - Fayetteville
Colorado
- Investigative Site US059 - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2025-06-23 |
| Est. Completion | 2027-07-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06959225
The ClinicalTrials.gov registry entry for NCT06959225 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 588-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib Cream is the first listed.
NCT06959225 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06959225 about?
NCT06959225 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)". The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
What is the current status of trial NCT06959225?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 550 participants. The study started on 2025-06-23. Estimated completion is 2027-07-11.
What conditions does trial NCT06959225 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06959225?
The interventions under investigation include: Ruxolitinib Cream (DRUG), Vehicle Cream (DRUG).
Who is sponsoring clinical trial NCT06959225?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06959225 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
RECRUITING · Phase 3
-
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.